39 Co-creation synergizes the collective expertise and insights to enhance sustainable outcomes. We are involving our suppliers in a collaborative process to achieve social and environmental stewardship. Sai’s own commitment to the Pharmaceutical Supply Chain Initiative (PSCI) and the Manufacture 2030 drives sustainability related actions in our supply chain, thereby collectively working towards responsible supply chain management. As a part of Manufacture 2030, we are engaging with a few of our key suppliers to help them disclose and reduce GHG emissions and take actions in the direction of Manufacture 2030 targets. We are taking the following approach to co-create value with our key suppliers for sustainability outcomes: 1. Create a sustainable procurement strategy As a signatory of the United Nations Global Compact (UNGC), we have committed to implement the ten principles of the UNGC and to make them part of our strategy, culture and day-to-day operations. Our suppliers review and acknowledge the Code of Supplier Conduct & Ethics Policy. As part of our renewed Sustainable Development Goals with FY 22 as baseline year, we have committed to engage with 100% of critical suppliers in committing to the code of supplier conduct and ethics over a five year period. We are currently sharing our Supplier Code of Conduct to our suppliers and getting it signed and acknowledged. The Code aims for strengthening mutual understanding of how sustainability should be practiced in day-to-day business. As a condition of doing business with Sai, the supplier is expected to comply with this Code and agree to uphold such values during their business association with us. The supplier maintains adequate documentation to demonstrate compliance with the principles of this Code and allows Sai access to check compliance. The goals towards making the sustainable procurement strategy functional are: • Commencing ESG Supplier Assessment Questionnaire in the reporting year FY 24 • Determination of ESG risks for key suppliers in FY 25 Being a CRDMO that works with innovator companies, we have several unique raw material requirements. To source these diverse requirements, we have developed a supplier base from across the world. We are also focusing on creating an indigenous supplier base for critical raw materials. Our multiple approaches include: • Multi sourcing approach for all KSMs from different geographical locations preferentially from domestic supplier base • Initially proceed with Chinese sources for developmental projects if non-availability of domestic / other geographical source and parallelly develop alternate domestic source • Strategically working with domestic CRO partners for development of new products on exclusive basis • Engage the supply partners by offering basket of products. Collaborate and hand hold the supply partner by Sai CFT team (TPTO - Third party technical overview) • Manufacturing in-house or at third partly with Sai’s technology Manufacture 2030 - Activate • Task force formed by CEO’s of 7 big pharma companies - AstraZeneca, GSK, Merck, Novo Nordisk, Roche, Samsung Biologics and Sanofi with World Health Organization to decarbonise healthcare supply chains • Work across the Healthcare Supply Chains to decarbonise operations & become greener, more efficient & circular • M 2030 runs a climate action program to reduce environmental impacts & help with product level changes Engaging with our suppliers Elements of Sai’s Supplier Code of Conduct and Ethics Policy Labour & Human Rights Health, Safety & Environmental Sustainability Business Integrity - Anti-Bribery Reporting of Unethical Practices & Grievance Addressal Mechanism Intellectual Property Supplier’s Compliance Commitment
RkJQdWJsaXNoZXIy MTIwMDc4NQ==